Clinical trial
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis…
NCT00146614 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00146614 |
|---|---|
| Title | Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation |
| Official title | Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Allogeneic Non-Myeloablative Peripheral Blood Stem Cell Transplantation |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Beth Israel Deaconess Medical Center Massachusetts General Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease, Hematologic Malignancies |
| Intervention type | Drug, Procedure |
| Interventions | Sirolimus, Tacrolimus, Methotrexate, Stem Cell Transplantation |
| Enrollment | 105 |
| Start date | Jul 1, 2002 |
| Primary completion | Apr 1, 2003 |
| Completion | Apr 1, 2003 |
| First posted | Sep 7, 2005 |
| Last update posted | Mar 8, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: